Medpace (NASDAQ:MEDP) & Ginkgo Bioworks (NYSE:DNA) Head to Head Comparison

Ginkgo Bioworks (NYSE:DNA) and Medpace (NASDAQ:MEDP) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability and institutional ownership.

Insider and Institutional Ownership

78.6% of Ginkgo Bioworks shares are owned by institutional investors. Comparatively, 78.0% of Medpace shares are owned by institutional investors. 12.7% of Ginkgo Bioworks shares are owned by company insiders. Comparatively, 20.5% of Medpace shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Ginkgo Bioworks and Medpace”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ginkgo Bioworks	$170.15 million	2.81	-$312.76 million	($5.01)	-1.46
Medpace	$2.53 billion	6.47	$451.12 million	$17.06	34.37

Medpace has higher revenue and earnings than Ginkgo Bioworks. Ginkgo Bioworks is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Ginkgo Bioworks and Medpace’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ginkgo Bioworks	-259.96%	-60.27%	-26.88%
Medpace	17.67%	110.15%	24.84%

Volatility & Risk

Ginkgo Bioworks has a beta of 1.78, suggesting that its stock price is 78% more volatile than the S&P 500. Comparatively, Medpace has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Ginkgo Bioworks and Medpace, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ginkgo Bioworks	2	1	0	0	1.33
Medpace	0	11	2	0	2.15

Ginkgo Bioworks presently has a consensus target price of $7.00, suggesting a potential downside of 4.50%. Medpace has a consensus target price of $584.18, suggesting a potential downside of 0.37%. Given Medpace’s stronger consensus rating and higher probable upside, analysts clearly believe Medpace is more favorable than Ginkgo Bioworks.

Summary

Medpace beats Ginkgo Bioworks on 12 of the 14 factors compared between the two stocks.

About Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

About Medpace

Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.